Details of the Drug Combination

General Information of Drug Combination (ID: DCNB7G5)

Drug Combination Name
Octreotide Motesanib
Indication
Disease Entry Status REF
Gastrointestinal Carcinoid Tumor Phase 1 [1]
Component Drugs Octreotide   DMHIDCJ Motesanib   DMZAL8C
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Octreotide
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [2]
Carcinoid syndrome 5B10 Approved [3]
Diabetic retinopathy 9B71.0 Approved [3]
Neuroendocrine cancer 2B72.1 Investigative [3]
Octreotide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Binder [6]
------------------------------------------------------------------------------------
Octreotide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Octreotide Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [8]
Thyrotropin subunit beta (TSHB) OTFDI39D TSHB_HUMAN Decreases Secretion [9]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [10]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
Indication(s) of Motesanib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Discontinued in Phase 3 [4]
Motesanib Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [11]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [11]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00427349) AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2055).
3 Octreotide FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5660).
5 [Effects of octreotide on necrosis of hepatocellular carcinoma xenografts in nude mice]. Ai Zheng. 2009 Jul;28(7):673-8. doi: 10.5732/cjc.009.10055.
6 Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
7 P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
8 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
9 Long-term efficacy and tolerability of octreotide treatment in acromegaly. Metabolism. 1992 Sep;41(9 Suppl 2):44-50. doi: 10.1016/0026-0495(92)90030-e.
10 [Octreotide induces apoptosis of human hepatoma cells by the mechanism of facilitating the Fas/FasL gene expression therein]. Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):716-8.
11 Clinical pipeline report, company report or official report of Amgen (2009).